(Total Views: 639)
Posted On: 10/25/2020 12:55:44 AM
Post# of 154806
“I don't have a good sense of which it is. I'm pretty sure that Ohm thinks it is #1, and I have faith in his opinion. But, I'm still not sure.“
IMO, I don’t think any investor truly knows what the DSMC recommendation actually means and we’re only only making assumptions on the information that’s available.
I’ll add that the DSMC’s recommendation to review mortality at 42 days could indicate that leronlimab may be reducing mortality more so at 42 days than at 28 days. It’s possible at 293 patients, the mortality at 42 days is statically reduced enough to halt the trial. I don’t know why they would want to review mortality at 42 days for any other reason. Maybe someone has an idea why?
IMO, I don’t think any investor truly knows what the DSMC recommendation actually means and we’re only only making assumptions on the information that’s available.
I’ll add that the DSMC’s recommendation to review mortality at 42 days could indicate that leronlimab may be reducing mortality more so at 42 days than at 28 days. It’s possible at 293 patients, the mortality at 42 days is statically reduced enough to halt the trial. I don’t know why they would want to review mortality at 42 days for any other reason. Maybe someone has an idea why?
(1)
(0)
